LON:ONC Oncimmune (ONC) Share Price, News & Analysis GBX 2.64 -0.26 (-8.97%) As of 02/21/2025 12:07 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades About Oncimmune Stock (LON:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncimmune alerts:Sign Up Key Stats Today's Range 2.25▼ 3.7850-Day Range 2.64▼ 15.8552-Week Range 2.25▼ 31Volume7.01 million shsAverage Volume635,992 shsMarket Capitalization£2.99 millionP/E Ratio0.30Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.Read More… Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesOncimmune Holdings Full Year 2024 Earnings: Misses ExpectationsFebruary 18, 2025 | finance.yahoo.comOncimmune schedules General Meeting for March approvalFebruary 12, 2025 | msn.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.February 22, 2025 | Brownstone Research (Ad)Oncimmune forecasts 33% revenue growth in 2025 after doubling in 2024February 10, 2025 | lse.co.ukOncimmune Holdings shares tick up as notes new contractsOctober 31, 2024 | lse.co.ukUPDATE: Oncimmune raises GBP2.2 million in equity as plannedOctober 21, 2024 | lse.co.ukSMALL CAP MOVERS: Pulsar Helium lifted by £5m IPO fundraiseOctober 18, 2024 | msn.comCancer Biopsy Market to Reach USD 85.03 Billion by 2032, Driven by Rising Cancer Incidence and Advances in Liquid Biopsy TechnologiesOctober 9, 2024 | finance.yahoo.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncimmune's stock was trading at GBX 14.35 at the beginning of 2025. Since then, ONC shares have decreased by 81.6% and is now trading at GBX 2.64. View the best growth stocks for 2025 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) released its earnings results on Monday, February, 10th. The company reported ($4.72) earnings per share (EPS) for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 2,277.74% and a net margin of 581.63%. How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE). Company Calendar Last Earnings2/10/2025Today2/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 8.87 Trailing P/E Ratio0.30 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.79 million Net Margins581.63% Pretax MarginN/A Return on Equity-2,277.74% Return on Assets-26.38% Debt Debt-to-Equity Ratio-412.06 Current Ratio1.14 Quick Ratio0.63 Sales & Book Value Annual Sales£1.86 million Price / Sales1.61 Cash FlowGBX 0.22 per share Price / Cash Flow11.96 Book ValueGBX (1.72) per share Price / Book-1.53Miscellaneous Outstanding Shares113,304,985Free FloatN/AMarket Cap£2.99 million OptionableNot Optionable Beta1.19 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (LON:ONC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.